Providing Communicative/Evidence-Based Integrative Kidney Cancer Care

According to an expert from University Hospitals, integrative oncology has a place in the treatment of patients with kidney cancer alongside palliative care, psycho-oncology, and physical therapy.

CancerNetwork® spoke with Santosh Rao, MD, in an interview during Kidney Cancer Awareness Month 2023 about how integrative oncology fits into multidisciplinary care strategies along with surgical, radiation, and medical oncology for patients with kidney cancer.

Rao, medical director of integrative oncology for University Hospitals Connor Whole Health and president-elect for the Society for Integrative Oncology, also indicated that integrative oncology consults are important tools for guiding patients using strong communication and evidence-based methods.

Transcript:

We have to think creatively. When I think of multidisciplinary care, it’s obviously [disciplines such as] surgical, radiation, and medical oncology which includes chemotherapy and immunotherapy. And you look for the issues that can come up throughout that whole journey. I don’t think of it as just integrative oncology. Integrative oncology is a broad term that involves a lot of different things.

But it has a certain place which can be alongside palliative care, psycho-oncology, and physical therapy. All these different things that we employ such as social work affect all patients with cancer in some ways or another at different times. Kidney cancer is no different. If you [have] depression, for example, what are the resources that can really help someone? That’s really the way I think about it.

The other thing we didn’t talk about is that many people have a lot of questions. One of the things that I do is integrative oncology consults. We will look at someone’s lifestyle and how they manage their stress, and we’ll also talk about questions that they have and what supplements and natural products they’re using.

That, as we’ve seen, is a huge business. Many people have all sorts of important questions, but if you don’t have any guidance, people are just going online and reading stuff. And we know that they don’t always bring it up with their physician. Also, many people don’t understand what to tell patients [about] what [products are] safe, not safe, et cetera. That’s important too. Whether you’re treating kidney cancer or another cancer, it comes up. Getting good guidance, communicating and collaborating, and doing it in an evidence-based way is also important.

Related Videos
PRGN-3005 autologous UltraCAR-T cells appear well-tolerated and decreases tumor burden in a population of patients with advanced platinum-resistant ovarian cancer.
Sara M. Tolaney, MD, MPH, discusses how, compared with antibody-drug conjugates, chemotherapy produces low response rates and disease control in the treatment of those with hormone receptor–positive, HER2-negative metastatic breast cancer.
Hope Rugo, MD, speaks to the importance of identifying patients with aromatase inhibitor–resistant, hormone receptor–positive, HER2-negative advanced breast cancer who are undergoing treatment with capivasertib/fulvestrant who may be at a high risk of developing diabetes or hyperglycemia.
Sara M. Tolaney, MD, MPH, describes the benefit of sacituzumab govitecan for patients with HER2-low metastatic breast cancer seen in the final overall survival analysis of the phase 3 TROPiCS-02 study.
An expert from Vanderbilt University Medical Center says that patients with relapsed/refractory multiple myeloma may be able to live a normal life following response to salvage treatment with bispecific monoclonal antibodies.
Andrew J. Armstrong, MD, MSc, spoke about the recent approval of olaparib plus abiraterone acetate and prednisone in patients with BRCA-mutant metastatic castration-resistant prostate cancer.
For clinicians practicing in the community, constant communication and education from those in institutions may help to produce the best quality of care for patients with multiple myeloma.
Ashley E. Rosko, MD, specializes in multidisciplinary care for elderly patients with multiple myeloma, and how to make treatment most accessible to them.
At first relapse, novel therapies are offered to patients with multiple myeloma at The Ohio State University Comprehensive Cancer Center-The James.
Ashley E. Rosko, MD, highlights potential changes on the horizon to the standard of care in multiple myeloma therapy, and discussed the personalization of treatment based on transplant eligibility.
Related Content